Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
JPEN J Parenter Enteral Nutr ; 46(7): 1623-1631, 2022 09.
Artículo en Inglés | MEDLINE | ID: mdl-35511709

RESUMEN

BACKGROUND: Short bowel syndrome (SBS) is considered a low prevalence disease. In Argentina, no registries are available on chronic intestinal failure (CIF) and SBS. This project was designed as the first national registry to report adult patients with this disease. METHODS: A prospective multicenter observational registry was created including adult patients with CIF/SBS from approved centers. Demographics, clinical characteristics, nutrition assessment, home parenteral nutrition (HPN) management, surgeries performed, medical treatment, overall survival, and freedom from HPN survival were analyzed. RESULTS: Of the 61 enrolled patients, 56 with available follow-up data were analyzed. At enrollment, the mean intestinal length was 59.5 ± 47.3 cm; the anatomy was type 1 (n = 41), type 2 (n = 10), and type 3 (n = 5). At the end of the interim analysis, anatomy changed to type 1 in 31, type 2 in 17, and type 3 in 8 patients. The overall mean time on HPN before enrollment was 33.5 ± 56.2 months. Autologous gastrointestinal reconstruction surgery was performed before enrollment on 21 patients, and afterward on 11. Nine patients (16.1%) were weaned off HPN with standard medical nutrition treatment; 12 patients received enterohormones, and 2 of them suspended HPN; one patient was considered a transplant candidate. In 23.7 ± 14.5 months, 11 of 56 patients discontinued HPN; Kaplan-Meier freedom from HPN survival was 28.9%. The number of cases collected represented 19.6 new adult CIF/SBS patients per year. CONCLUSION: The RESTORE project allowed us to know the incidence, the current medical and surgical approach for this pathology, as well as its outcome and complications at dedicated centers.


Asunto(s)
Enfermedades Intestinales , Insuficiencia Intestinal , Nutrición Parenteral en el Domicilio , Síndrome del Intestino Corto , Adulto , Argentina/epidemiología , Enfermedad Crónica , Humanos , Enfermedades Intestinales/terapia , Estudios Prospectivos , Sistema de Registros , Estudios Retrospectivos , Síndrome del Intestino Corto/complicaciones , Síndrome del Intestino Corto/terapia
2.
JPEN J Parenter Enteral Nutr ; 45(5): 1072-1082, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-32740966

RESUMEN

BACKGROUND: Teduglutide, a semisynthetic analogue of glucagon-like peptide-2 (sGLP-2), increases intestinal absorption of fluids and nutrients, reducing the need for parenteral nutrition (PN). This report aims to describe our experience with sGLP-2 in a cohort of adult patients with short-bowel syndrome. METHODS: This is a prospective observational study on adult patients initially evaluated in our specialized intestinal rehabilitation program that received sGLP-2 from June 2014 to March 2020. RESULTS: Autologous gastrointestinal reconstruction surgery (AGIRS) was performed in 108 patients; 68.5% (74 of 108) achieved intestinal sufficiency with standard medical therapy. Seventeen patients were treated with sGLP-2; 66.5% (8 of 12) received treatment for a mean time of 25.8 weeks (3.4-54.0) and could suspend PN. One patient reinitiated treatment due to renal lithiasis and acute renal failure. Currently, 7 of 12 patients (53.8%) continue without PN for a mean time of 165.6 weeks. Volume, energy, and days of PN were reduced in all patients. No serious adverse events were registered. Four of 7 patients (57.1%) who discontinued PN could also discontinue sGLP-2. Therefore, the use of sGLP-2 increased the overall success rate of PN independency after AGIRS to 76% (82 of 108). CONCLUSION: This study confirmed that sGLP-2 should be considered as part of the standard therapy for postsurgical medical rehabilitation treatment in patients with chronic intestinal failure. We add to the current knowledge that some patients can discontinue both PN and sGLP-2 in the long term, achieving complete recovery of their quality of life.


Asunto(s)
Calidad de Vida , Síndrome del Intestino Corto , Adulto , Fármacos Gastrointestinales/uso terapéutico , Péptido 2 Similar al Glucagón/uso terapéutico , Humanos , Nutrición Parenteral , Derivación y Consulta , Síndrome del Intestino Corto/tratamiento farmacológico
3.
Artículo en Inglés | MEDLINE | ID: mdl-17981101

RESUMEN

The aqueous solution behaviour of polyethyleneimine (a cationic synthetic polymer) in the presence of anions (such as citrate and phosphate) was studied by means of turbidimetry. The variation of the absorbance at 420 nm of dilute mixture with pH, the polymer concentration and the ionic strength were examined. The mixture of polyethyleneinine citrate or polyethyleneinine phosphate behaves as a pseudo polyampholyte with an isoelectric point of 5.5 and 6.2 for phosphate and citrate respectively and a precipitation pH range between 3.5 and 8.0. Pepsin was completely precipitated with the polymer anion complex within this pH interval. Citrate showed a better precipitation effect than phosphate did. The precipitate was reversibly dissolved in NaCl (for concentrations higher than 0.2 M) and pepsin kept its biological activity. Studies of pepsin thermal stability (by differential scanning calorimetry) revealed that the polyethyleneimine presence increased the enzyme denaturation temperature. The circular dichroism spectrum of pepsin showed a non-significant loss of secondary and tertiary enzyme structure by the polyethyleneimine. However, the polymer presence increased the biological activity of pepsin.


Asunto(s)
Tampones (Química) , Citratos , Organofosfatos , Pepsina A/aislamiento & purificación , Polietileneimina , Estabilidad de Enzimas , Concentración de Iones de Hidrógeno , Nefelometría y Turbidimetría , Pepsina A/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...